Clinical Studies: First defeatHIV Clinical Study Is Enrolling!
First defeatHIV Clinical Study Is Enrolling!
We are excited to announce recruitment for the first defeatHIV clinical study is open! This is an important step in our HIV eradication efforts and as such, we will be updating defeatHIV.org to include further information on our clinical studies for HIV patients. Read on for study details, eligibility criteria and clinic contact information.
Purpose: The purpose of the treatment on this study is to replace bone marrow cells with healthy cells donated by a person with a healthy immune system. The new bone marrow or hematopoietic stem cells have the ability to grow into new blood and immune systems. We believe that HAART may give us a new way to help control the HIV and prevent it from infecting the new bone marrow cells. We will monitor the level of HIV in the latent reservoir to determine whether HAART drugs can continue to control or even reduce HIV after hematopoietic stem cell transplantation (HSCT).
b. have a HIV load <5000 copies/ml.
b. have a HIV load <50 copies/ml, and c. have a CD4 count <100 cells/ml.
Patients must have an HLA-matched donor.
Patients must be <65 years old.
Contact: For more information, contact the Clinical Coordinator Office at the Seattle Cancer Care Alliance (1-800-804-8824) and reference protocol number 1410.
defeatHIV clinical studies are performed in Seattle, WA at the Seattle Cancer Care Alliance (SCCA). The SCCA is the treatment arm of the world-renowned Fred Hutchinson Cancer Research Center, and operates the largest bone marrow transplant program in the world.